CLINICAL_TRIALS
trial_result
· 2019-01-23
Clinical Trial Update: BKM120 For Triple Negative Breast Cancer [Phase 2]
Summary
A Phase 2 trial of buparlisib (BKM120) for triple-negative breast cancer has completed and results were posted in January 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-01-23